AU7578796A - Topical compositions containing a beta-cyclodextrin and an amino polysaccharide - Google Patents

Topical compositions containing a beta-cyclodextrin and an amino polysaccharide

Info

Publication number
AU7578796A
AU7578796A AU75787/96A AU7578796A AU7578796A AU 7578796 A AU7578796 A AU 7578796A AU 75787/96 A AU75787/96 A AU 75787/96A AU 7578796 A AU7578796 A AU 7578796A AU 7578796 A AU7578796 A AU 7578796A
Authority
AU
Australia
Prior art keywords
cyclodextrin
composition
polysaccharide
amino
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU75787/96A
Other versions
AU719360B2 (en
Inventor
Selwyn Everest-Todd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Everest-Todd Research & Development Ltd
Original Assignee
Everest Todd Research & Dev Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Everest Todd Research & Dev Li filed Critical Everest Todd Research & Dev Li
Publication of AU7578796A publication Critical patent/AU7578796A/en
Application granted granted Critical
Publication of AU719360B2 publication Critical patent/AU719360B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

TOPICAL COMPOSITIONS CONTAINING A BETA-CYCLODEXTRIN AND AN AMINO POLYSACCHARIDE
This invention relates to a treatment material applicable to wounds, injuries and a wide variety of diseases of the skin to reduce pain, inflammation and to increase the rate of healing of the affected area of the skin.
The chemistry of the inflammation processes of the skin has revealed the role of the enzyme phospholipase in the hydrolysis of lecithin and the release of free arachidonic acid. Arachidonic acid is rapidly transformed to the leukotriene via lipoxygenase, thereby producing pain and inflammation.
According to the present invention this train of events can be halted by the topical application of clathrating agents in particular a composition for topical application for the relief of inflammation comprising an inert powder, or a gel, cream or dispersion or the like inert carrier, together with a β- cyclodextrin and an amino saccharide or polysaccharide.
Combinations of amino saccharides or polysaccharides and cyclodextrins according to the invention have been shown to be beneficial in the treatment of skin disorders such as eczema and psoriasis, and have unexpectedly been found to be more effective than either component alone. By incorporating the amino polysaccharide and cyclodextrin with a cross linked acrylic polymer, in accordance with a preferred embodiment, a dry sterile dressing for the treatment wounds or injuries may be produced to which sterile water may be added immediately prior to application.
B-cyclodextrin is a cyclic polymer containing seven D-glucose units and has a doughnut-shaped molecular structure including an interior cavity which receive other molecules and form clathrate compounds therewith. While the efficacy of the invention does not depend on the correctness of the theory, it is believed that the cyclodextrin clathrates the arachidonic acid produced by the wound and thus effectively removes it and so prevents or reduces the pain and inflammation associated with it.
Preferably, the amino saccharides and polysaccharides employed include chitin and products derived from chitin, for example by hydrolysis, to produce n-acetyl glucosamine which can then be de-acylated to give glucosamine or glucosamine hydrochloride. Such compounds have analgesic or or anti-inflammatory properties and the efficacy thereof has been unexpectedly found to be enhanced when used with cyclodextrin an accordance with the invention.
Further combinations of these ingredients have been employed to demonstrate the broad range of applications in creams, gels and dispersions in the treatment or prevention of a wide range of diseases or injuries.
The following examples will serve or illustrate the novelty and benefits of this invention.
Example I
50. Og of glucosamine hydrochloride 50. Og of dimethyl β . cyclodextrin made up to 1 litre with sterile water.
The solution was then added to a mixture of 1 kg. coconut oil and 40g of an organo phosphate ester emulsifier maintained at 50°C. After agitation and cooling this produced a lotion suitable for topical application to the skin to combat inflammation. Examp le I I
4. Og of Alcosorb polymers
10. Og glucosamine hydrochloride and
15. Og β . cyclodextrin iodine clathrate
The mixture was mixed thoroughly and placed within a sachet made from bonded synthetic polymers measuring 10 x 15 cms. The sealed sachet was maintained in a dry, sterile condition prior to use.
Example III
40g Alcosorb polymers lOOg glucosamine hydrochloride
150g dimethyl β. cyclodextrin
The mixture was mixed thoroughly prior to the addition of 1800ml of sterile water, added with constant agitation for a period of five (5) minutes.
The resultant gel was then preserved in sterile containers.
Example IV
lOOg chitin Poly-(l-4) β-D-N-acetylglucosamine 50g β . cyclodextrin 50g Alcosorb
The ingredients were admixed and ground to a particle size of 50 microns. The resultant powder was suitable for inclusion with synthetic polymers of incorporation with fabricated polymers.
The preparations illustrated but not limited by Examples I to IV were then subjected to a series of tests as demonstrated by the following examples. Exa ple VI
The lotion prepared as in Example I_ was applied to the affected tissue on patients suffering from psoriasis or eczema. All reported relief from pruritis within 10 minutes after application and regeneration of dermal tissue was observed on the fourth day.
Example VI
A sachet, produced as in Example I_I, was immersed in 0.5 litres of sterile water for five (5) minutes and applied to a second degree burn on a patients forearm. The dressing was bandaged in place for twenty four hours. Relief from pain occurred within minutes and when the dressing was removed the healing process had commenced.
Example VII
Gel, produced as in Example III , was applied to insect bites, minor scalds and burns in a variety of patients.
The response obtained in all cases was the rapid relief from pain and promotion of healing.
Example VIII
The powder produced as in Example IV was incorporated in the layer of fabric used to produce sanitary wear. In the case of infants the incidence of infection caused by the micro organism Candida albicans, known as nappy rash, was significantly reduced. Other applications for the reduction of infection by this organism are related to age and sex.
In each of the Examples I to IV the dimethyl β . cyclodextrin and β . cyclodextrin may be exchanged without detracting from the principle of the invention. Similarly the amino polysaccharides as a group display similar characteristics from a therapeutic standpoint although the chemical and or physical properties may differ.
Example IX
A colloidal suspension was prepared from a combination of chitin, chitosan and glucosamine having a particle size of less than 5 microns in an aqueous solution of /3-cyclodextrin in the following manner:
40g chitin (poly(1-4) -N-acetyl-D-glucosamine)
40g chitosan (poly(1-4) -D-glucosamine)
20g glucosamine
The above ingredients were introduced with agitation into an aqueous solution containing β-cyclodextrin and the whole made up to a total volume of 1 litre.
A non-woven polyester fabric was wetted with this suspension by short term immersion (1-2 seconds, nip rollers) then dried prior to forming into 10cm squares for use in surgical dressings as the contact surface with the perturbed tissue. When applied to lacerated tissue, relief from pain occured within minutes and the healing process was accelerated.
Analysis of the treated fabric showed that the level of the combined ingredients was 1.7% w/w. It is believed that a combination of saccharides and polysaccharides as in this Example is particularly effective.

Claims (8)

CLAI S
1. A composition for topical application for the relief of inflammation comprising an inert powder, or a gel, cream or dispersion or the like inert carrier, together with a cyclodextrin and an amino saccharide or polysaccharide.
2. A composition as claimed in claim 1 in which the amino polysaccharide and cyclodextrin are incorporated with a cross- linked acrylic polymer to form a dry sterile dressing for the treatment of wounds or injuries.
3. A composition as claimed in either of claims 1 or 2 in which the cyclodextrin is β-cyclodextrin or dimethyl β- cyclodextrin.
4. A composition as claimed in any of claims 1 to 3 wherein both a saccharide and a polysaccharide is present.
5. A composition as claimed in any of claims 1 to 4 made into a cream with water and coconut oil by virtue of an organo¬ phosphate ester emulsifier.
6. A composition as claimed in any of claims 1 to 4 made into a gel with water and alcosorb polymers.
7. A composition as claimed in any of claims 1 to 4 in powder form mixed with alcosorb polymers for mixing with water prior to use.
8. A composition substantially as hereinbefore particularly described with reference to the foregoing examples.
AU75787/96A 1995-11-15 1996-11-13 Topical compositions containing a beta-cyclodextrin and an amino polysaccharide Ceased AU719360B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9523335A GB2307176A (en) 1995-11-15 1995-11-15 Anti-inflammatory clathrating agents for topical use
GB9523335 1995-11-15
PCT/GB1996/002768 WO1997017977A1 (en) 1995-11-15 1996-11-13 Topical compositions containing a beta-cyclodextrin and an amino polysaccharide

Publications (2)

Publication Number Publication Date
AU7578796A true AU7578796A (en) 1997-06-05
AU719360B2 AU719360B2 (en) 2000-05-04

Family

ID=10783900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75787/96A Ceased AU719360B2 (en) 1995-11-15 1996-11-13 Topical compositions containing a beta-cyclodextrin and an amino polysaccharide

Country Status (6)

Country Link
EP (1) EP0863761A1 (en)
AU (1) AU719360B2 (en)
CA (1) CA2237758A1 (en)
GB (1) GB2307176A (en)
NZ (1) NZ322119A (en)
WO (1) WO1997017977A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4443689A1 (en) * 1994-12-08 1996-06-13 Krauss Maffei Ag Closing unit for an injection molding machine
GB9626963D0 (en) * 1996-12-27 1997-02-12 Everest Todd Res & Dev Improved surgical dressings and method of preparation
TWI242015B (en) * 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
EP1127574A1 (en) * 2000-02-22 2001-08-29 Food Industry Research and Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
US6653294B2 (en) 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
DE10126396A1 (en) * 2001-05-31 2002-12-05 Beiersdorf Ag Cosmetic or dermatological preparations containing glucosamine, useful e.g. for treatment, care and prophylaxis of sensitive skin and treatment of inflammatory conditions such as eczema or psoriasis
LU91353B1 (en) * 2007-08-08 2009-02-09 Recipe Holding S A Glucosamine 1200mg, sachet
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
KR20150107742A (en) 2012-12-11 2015-09-23 자피오텍 게엠베하 Delphinidin for combating melanoma cells
EP2907518A1 (en) * 2014-02-14 2015-08-19 SapioTec GmbH Analgesic
EP2913366A1 (en) * 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin complex
US10835584B2 (en) * 2016-06-17 2020-11-17 Nuvothera, Inc. Systems for treating dermal inflammatory conditions
AU2020204925A1 (en) 2019-01-03 2021-07-22 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
WO2021100044A1 (en) 2019-11-20 2021-05-27 Avgol Ltd. Methods of merging cyclodextrin hosts with nonwoven finishing to form smart fabrics containing various beneficial agents and products made from the methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5423966B2 (en) * 1972-11-11 1979-08-17
JPS5788123A (en) * 1980-11-20 1982-06-01 Kotsukusu Jiyaagen Beta-cyclodextrin as antiacne
JPS58126810A (en) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd Ophthalmic anti-inflammatory solution and preparation thereof
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS61221120A (en) * 1985-03-28 1986-10-01 Nitto Electric Ind Co Ltd Medical material for external use
JPH0613448B2 (en) * 1985-07-02 1994-02-23 三省製薬株式会社 Cutaneous elastic fibrosis preventive agent
JPH0249711A (en) * 1988-08-11 1990-02-20 Nikkei New Bijinesu Kk Novel cream for foundation cosmetic
GB8910069D0 (en) * 1989-05-03 1989-06-21 Janssen Pharmaceutica Nv Method of topically treating acne vulgaris
FR2647015B1 (en) * 1989-05-17 1994-05-06 Cird AQUEOUS GEL BASED ON RETINOIC ACID AND ITS USE IN HUMAN MEDICINE AND COSMETICS
JPH04334321A (en) * 1991-05-09 1992-11-20 Unitika Ltd Preventive for dermatic inflammation
DE4220736A1 (en) * 1992-06-25 1994-01-05 Puetter Medice Chem Pharm Inclusion complexes of polymerized cyclodextrins with pharmaceutically active substances

Also Published As

Publication number Publication date
GB9523335D0 (en) 1996-01-17
NZ322119A (en) 1998-09-24
WO1997017977A1 (en) 1997-05-22
CA2237758A1 (en) 1997-05-22
EP0863761A1 (en) 1998-09-16
GB2307176A (en) 1997-05-21
AU719360B2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
AU719360B2 (en) Topical compositions containing a beta-cyclodextrin and an amino polysaccharide
Hamedi et al. Chitosan based hydrogels and their applications for drug delivery in wound dressings: A review
EP1483299B1 (en) Cell wall derivatives from biomass and preparation thereof
AU2011334627B2 (en) Glucan compositions
KR100343293B1 (en) Dried hydrogel from hydrophylic-hygroscopic polymer
KR101155884B1 (en) Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound
AU639163B2 (en) Methyl pyrrolidinone chitosan, production process and uses thereof
KR20200081403A (en) Antibacterial superabsorbent composition
JP2004211101A (en) POLY-beta-1->4-N-ACETYLGLUCOSAMINE
MX2010007902A (en) Chitosan gel for dermatological use, production method therefor and use of same.
CA2520014C (en) Process for the manufacture of alginate-containing porous shaped articles
JP5933178B2 (en) Hydrogel of chitosan carboxyalkylamide, process for its preparation, and anhydrous products, dermatological compositions and cosmetic compositions
US11058712B2 (en) Film for topical application in the treatment of skin lesions and method of obtaining and applying same
WO2009032325A1 (en) Shaped items containing a human pheromone component
JPH08245401A (en) Skin protecting agent
KR20200126078A (en) Antimicrobial and Antioxidant Chitosan-Mandelic acid Polyelectrolyte Complexes and Aqueous Compositions Theirof
WO1990006124A1 (en) Formulations for treating slow and non-healing wounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired